Munger Mode rating: 2 out of 5 — Sell. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
Before we say a word about genomics, moats, or margins, we have to put the central fact on the table, because it changes the nature of the question entirely: on July 20, 2026, Personalis agreed to be acquired by Tempus AI (Nasdaq: TEM) for $16.25 per share. The deal values Personalis at roughly a $1.5 billion enterprise value net of the stake Tempus already owns, and management expects it to close in late 2026 or early 2027, subject to a Personalis shareholder vote, regulatory clearance, and — this matters — a Tempus share-price condition. So a fellow buying PSNL at today's $13.52 is not, in any honest sense, buying a business. He is buying a merger-arbitrage instrument. The entire return case is the roughly 20% gap between $13.52 and the $16.25 headline price.
Recent filings analysed: 8-K (2026-08-04), 10-Q (2026-08-04), 8-K (2026-07-20), 8-K (2026-07-20).
Stock screener · Superinvestor 13F holdings · Analyst sentiment · Market valuation